Technology Crossover Management X Ltd. Invests $4.76 Million in GoodRx Holdings, Inc. $GDRX

Technology Crossover Management X Ltd. bought a new position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) during the 2nd quarter, Holdings Channel reports. The firm bought 1,653,566 shares of the company’s stock, valued at approximately $4,762,000. GoodRx accounts for about 0.6% of Technology Crossover Management X Ltd.’s investment portfolio, making the stock its 6th largest holding.

A number of other institutional investors have also made changes to their positions in GDRX. Quarry LP acquired a new position in GoodRx during the 3rd quarter worth about $33,000. Cetera Investment Advisers acquired a new stake in GoodRx in the 2nd quarter valued at about $50,000. Boothbay Fund Management LLC acquired a new stake in GoodRx in the 3rd quarter valued at about $43,000. Meridian Wealth Management LLC bought a new position in shares of GoodRx in the fourth quarter worth about $29,000. Finally, Shay Capital LLC bought a new position in shares of GoodRx in the third quarter worth about $47,000. 63.77% of the stock is owned by institutional investors.

GoodRx Stock Down 1.9%

Shares of GoodRx stock opened at $3.65 on Wednesday. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.74. GoodRx Holdings, Inc. has a 12 month low of $1.77 and a 12 month high of $5.81. The business has a fifty day simple moving average of $3.07 and a 200 day simple moving average of $2.61. The stock has a market cap of $1.25 billion, a PE ratio of 91.27, a price-to-earnings-growth ratio of 1.77 and a beta of 1.60.

GoodRx (NASDAQ:GDRX) last released its earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share for the quarter, meeting the consensus estimate of $0.08. The firm had revenue of $200.41 million for the quarter, compared to analyst estimates of $193.23 million. GoodRx had a return on equity of 7.22% and a net margin of 2.07%.The company’s quarterly revenue was down 1.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.09 earnings per share. Research analysts predict that GoodRx Holdings, Inc. will post 0.16 EPS for the current year.

Wall Street Analysts Forecast Growth

GDRX has been the topic of several research analyst reports. Leerink Partners set a $5.00 price target on shares of GoodRx in a research note on Thursday, August 6th. Wall Street Zen raised GoodRx from a “hold” rating to a “buy” rating in a report on Saturday. TD Cowen increased their price objective on GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Citigroup increased their price objective on GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Finally, Wells Fargo & Company lifted their target price on GoodRx from $3.50 to $5.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Four analysts have rated the stock with a Buy rating, six have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $4.14.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.